お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
613021

世界の急性骨髄性白血病 (AML) 治療薬市場:成長率、動向、予測

Acute Myeloid Leukemia Market - Growth, Trends, and Forecast (2019 - 2024)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 115 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=107.49円
世界の急性骨髄性白血病 (AML) 治療薬市場:成長率、動向、予測
出版日: 2019年02月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 115 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の急性骨髄性白血病 (AML) 治療薬市場について調査分析し、市場概要、市場力学、市場区分、地域別の市場分析、競合情勢、主要企業などについて、体系的な情報を提供しています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場概要

  • 現在の市場シナリオ
  • ファイブフォース分析

第6章 促進要因・抑制要因・機会・課題分析

  • 市場促進要因
  • 市場抑制要因
  • 機会
  • 主な課題

第7章 市場区分

  • 化学療法別
  • 区分:地域別

第8章 競合情勢

  • M&A分析
  • 契約・提携・パートナーシップ
  • 新製品発売

第9章 企業プロファイル

  • GENMAB A/S
  • GLAXOSMITHKLINE
  • BRISTOL MYER SQUIBB
  • NOVARTIS AG
  • ROCHE
  • CELEGENE CORPORATION
  • エーザイ
  • CLAVIS PHARMA
  • AMBIT BIOSCIENCE CORPORATION

第10章 市場の将来見通し

目次
Product Code: 46400

Market Overview

The global acute myeloid leukemia market was valued at USD 701.6 million in 2018, and is estimated to be valued at USD 1,539.99 million in 2024, witnessing a CAGR of 14.0%. The key factors propelling the growth of this market are high Incidence and prevalence of acute myeloid leukemia, advancements in pharmacology and molecular biology to promote drug development, and increasing investments in R&D by the pharmaceutical companies.

The American Cancer Society's estimates for leukemia in the United States, for 2019, indicates that approximately 61,780 new cases of leukemia and 22,840 deaths from leukemia are expected to occur in the country. Among them, the number of new cases of acute myeloid leukemia (AML) will be around 21,450, from which most of the population will be adults. In terms of mortality, the society has estimated that there will be around 10,920 deaths due to AML, in the country. This statistics shows that there is a huge number of people that are prone to suffer from acute myeloid leukemia, which may directly impact the growth of the AML market in the United States.

In addition, the global rise in the incidence of AML, along with increased mortality due to the disease, is expected to create a huge demand for AML therapeutics, thus, augmenting the global AML market.

Scope of the Report

This report estimates the global acute myeloid leukemia market and includes a detailed analysis of cytarabine, anthracycline drugs, and daunomycin.

Acute myeloid leukemia is also known as acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, or acute non-lymphocytic leukemia. In acute myeloid leukemia, there is a rapid production of abnormal white blood cells that get collected in the bone marrow and disturb the production of normal blood cells. White blood cells guard the body against infections caused by bacteria.

Key Market Trends

Cytarabine is Expected to hold its Highest Market Share in the Chemotherapy Segment

In the chemotherapy segment of the acute myeloid leukemia market, cytarabine is believed to have the largest market size and is expected to witness a CAGR of 14.3% during the forecast period.

Most of the times, surgery and radiation therapy in cancer patients remove, kill, or damage cancer cells in a certain area, but chemotherapy works throughout the whole body and gives better results. Chemotherapy is necessary to kill the cancer cells that are spread (metastasized) across different parts of the body. On the contrary, surgery and radiation only attack or kill the tumor that is located in a specific part. Since cancer is the disease which, most of the times, spreads across the whole body in a short period of time, oncologists choose to perform chemotherapy for better results.

Cytarabine is used to treat different forms of leukemia, including acute and chronic myelogenous leukemia (AML and CML), acute lymphocytic leukemia (ALL), and acute promyelocytic leukemia (APL). It is also used to treat Hodgkin's lymphoma, as well as meningeal leukemia and other types of lymphoma (cancers found in the lining of the brain and spinal cord). Due to its effectiveness in the treatment of acute myeloid leukemia, cytarabine is being widely used during chemotherapy. Organizations that are working for cancer, such as Macmillan Cancer Support, have stated that cytarabine is more effective for acute myeloid leukemia, which is why the drug is used widely; therefore, this sub-segment is expected to have a large market share in the chemotherapy segment.

North America Dominates the Market and is Expected to do Same in the Forecast Period

North America currently dominates the market for acute myeloid leukemia and is expected to continue its stronghold for a few more years. The United States holds the largest share of the market. The United States has a unique healthcare system among the developed countries. However, the cost of hospitals is very high in the country; the government or private insurance cover it. Most of the people opt for private insurance as government insurance has its own limitations. The American Cancer Society had estimated around 21,380 new cases of acute myeloid leukemia (AML) and approximately 10,590 deaths from AML in the United States, in 2016.

According to this society, these statistics involve a large percentage of the adult population. The increasing number of AML patients in the United States require proper medical procedures to increase their life expectancy. The rising prevalence of AML in the country is the prime factor responsible for the growth of the market in the country.

Competitive Landscape

The acute myeloid leukemia market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new techniques with good results. Companies, like Novartis AG, Teva Pharmaceuticals, Pfizer, Bristol Myer Squibb, and Sanofi-Aventis (Genzyme Corporation), hold substantial shares in the market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 High Incidence and Prevalence of Acute Myeloid Leukemia
    • 4.2.2 Advancement in Pharmacology and Molecular Biology to Promote Drug Development
    • 4.2.3 Increasing Investments in R&D
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulations on Drugs
    • 4.3.2 Complications Related to Chemotherapy
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Chemotherapy
    • 5.1.1 Cytarabine
    • 5.1.2 Anthracycline Drugs
      • 5.1.2.1 Daunomycin
      • 5.1.2.2 Idarubicin
      • 5.1.2.3 Mitoxantrone
    • 5.1.3 Alkylating Agents
    • 5.1.4 Anti-metabolites
    • 5.1.5 Tyrosine Kinase Inhibitors
      • 5.1.5.1 Dasatinib (Sprycel)
      • 5.1.5.2 Imatinib (Gleevec)
    • 5.1.6 Hormonal Therapy
    • 5.1.7 Other Chemotherapies
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East & Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East & Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Celegene Corporation
    • 6.1.2 Novartis AG
    • 6.1.3 Genmab AS
    • 6.1.4 Eisai Co. Ltd
    • 6.1.5 Sanofi-Aventis (Genzyme Corporation)
    • 6.1.6 Teva Pharmaceutical (Cephalon Inc.)
    • 6.1.7 Pfizer Inc.
    • 6.1.8 Bristol-Myers Squibb Company
    • 6.1.9 Sunesis Pharmaceuticals Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.